Retinalamin Research for Age-Related Macular Degeneration
An evidence-based overview of research examining Retinalamin in the context of age-related macular degeneration. This page synthesizes findings from peer-reviewed literature.
Research Summary
Retinalamin is registered in Russia for AMD treatment. Russian clinical studies report stabilization or improvement of visual function in dry AMD patients. Treatment typically involves parabulbar or intramuscular injections. No Western clinical trials have evaluated these claims; all evidence comes from Russian studies.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Age-Related Macular Degeneration
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Retinalamin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.